FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     ZACCARDELLI DAVID						2. Issuer Name <b>and</b> Ticker or Trading Symbol Verona Pharma plc [ VRNA ]										ationship k all app Direc	,	ng Pe	rson(s) to I		
(Last) 3 MORE	(Last) (First) (Middle)  3 MORE LONDON RIVERSIDE							3. Date of Earliest Transaction (Month/Day/Year) 11/01/2021									eer (give title w) President a		Other (specify below) and CEO		
(Street) LONDO (City)	DNDON X0 SE1 2RE						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Table	I - N	Non-Deriva	ative	Secui	rities	Ac	quir	ed, D	ispo	sed of	f, or E	Benefic	ially	/ Own	ed				
Date			2. Transaction Date (Month/Day/Y	Execution ear) if any				3. Transaction Code (Instr. 8)		4. Securities Acqui Disposed Of (D) (Ir					5. Amount of Securities Beneficially Owned Following Reported		Forr (D) (	wnership m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								ſ	Code V		Amou	unt	(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)					
Ordinary	Shares <sup>(1)</sup>			11/01/202	21				F <sup>(2)</sup>		454	4,848	D	\$0.64	(3)	16,8	397,408	D			
Ordinary	ary Shares <sup>(1)</sup> 11/02/202				21	1			S <sup>(4)</sup>		52,	,056	D	\$0.641	1 <sup>(5)</sup>	<sup>5)</sup> 16,845,352 <sup>(6)</sup>			D		
		Tal	ble I	II - Derivati (e.g., ρι												Owne	d				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Ye.	cution Date, ny	4. Transaction Code (Instr 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Exp (Mo	piration	ercisable and n Date ay/Year)		7. Titl Amou Secur Under Derive Secur 3 and	int of ities rlying ative ity (Instr.	Dei	Price of ivative curity str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Owners Form: Direct ( or Indir (I) (Insti	Ownership	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Dat Exe	te ercisabl		xpiration ate	Title	Amount or Number of Shares							

## **Explanation of Responses:**

- 1. Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
- 2. Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units.
- 3. The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on October 29, 2021 divided by eight (8).
- 4. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported Restricted Share Units.
- 5. The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from \$0.6525 to \$0.6313. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 5
- 6. Consists of (i) 10,535,528 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 1,316,941 ADSs); and (ii) 6,309,824 Ordinary Shares underlying 788,728 ADSs.

/s/ Claire Poll, Attorney-infact for David Zaccardelli

11/03/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.